As illustrated in Figure 2, pooled analyses of cardiovascular outcome trials have demonstrated that GLP-1 RAs reduce major adverse cardiovascular events (MACEs) by 14% (HR = 0.86, 95% CI 0.79–0.94) in patients with type 2 diabetes, with additional significant benefits including 13% reduction in cardiovascular death, 16% reduction in nonfatal stroke, and 10% reduction in hospitalization for heart failure [85]. This evidence concerns the gene GLP1R and heart failure.